Reinvigorating The Coronary Stent Market: Can Bioresorbable Scaffolds Do The Job?

Bioresorbable coronary scaffolds could transform the coronary stenting market once they become widely available. But although there are more than a dozen companies developing these promising devices, there are still a number of unanswered questions – chief among them, how effectively they will compete against existing and upcoming next-generation durable stents, and how much of a price premium bioresorbable devices will be able to command.

With percutaneous coronary intervention (PCI) procedure volumes continuing to decline in the US and Europe, and coronary drug-eluting stents (DES) becoming commoditized as a result of increased competition and pricing pressures, some may wonder when (and where) the DES market, currently valued at about $1.3 billion in the US and about $4 billion worldwide, will bottom out. However, perhaps the more significant question is whether or not there is a next-generation technology in the pipeline with the ability to re-energize this space and return it to the growth track seen in years past. As is often the case, the answer is not a simple one. Although DES market leaders are spending millions developing next-generation products, it remains to be seen just how successful they will be and how much of a price premium they will be able to command.

Many of these new devices have improved stent platforms, including thinner struts and thinner, resorbable polymer coatings, designed to improve...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.